PT  - JOURNAL ARTICLE
AU  - Williams, E
AU  - John, NA
AU  - Blackstone, J
AU  - Brownlee, W
AU  - Frost, C
AU  - Greenwood, J
AU  - Chataway, J
AU  - ,
TI  - TP1-11 MS-STAT2: a phase 3 trial of high dose simvastatin in secondary progressive multiple sclerosis
AID  - 10.1136/jnnp-2019-ABN.40
DP  - 2019 Mar 01
TA  - Journal of Neurology, Neurosurgery & Psychiatry
PG  - e13--e13
VI  - 90
IP  - 3
4099  - http://jnnp.bmj.com/content/90/3/e13.1.short
4100  - http://jnnp.bmj.com/content/90/3/e13.1.full
SO  - J Neurol Neurosurg Psychiatry2019 Mar 01; 90
AB  - Objectives Disease modifying treatment for secondary progressive multiple sclerosis (SPMS) represents a major unmet need. We outline here the rationale for the MS-STAT2 trial – a phase 3 study of simvastatin in decreasing clinical progression in SPMS. MS-STAT2 will be a landmark study not only for patients with SPMS, but also for the area of drug repurposing and academically led clinical trials as a whole.Design Multicentre, double blind, parallel group randomised placebo-controlled trial. It follows the positive outcome from the phase 2 MS-STAT1 trial, which demonstrated a 43% reduction in the annualised rate of brain atrophy compared to placebo.1 Subjects 1180 patients with SPMS with an expanded disability status scale (EDSS) score of 4.0–6.5. Patients need to show evidence of disease progression over the preceding 2 years.Methods Subject will be recruited at 28 sites across the UK, and randomised to simvastatin 80 mg or matched placebo and assessed every 6 months over the 3 year trial.Results The primary outcome measure is time to 6 month confirmed disability progression, based on change in Expanded Disability Status Scale (EDSS) scores compared to baseline. Secondary outcomes include assessments of cognition, walking, upper limb function and vision. Sub-studies will include advanced imaging outcomes, ocular coherence tomography and fluid biomarkers.Conclusions MS-STAT2 is set to be a pivotal trial for SPMS. Recruitment has now commenced and further sites are welcome.ReferenceChataway J, et al. MS-STAT. Lancet2014;383:2213–21.